Abeona Therapeutics Inc.
ABEO
$5.74
-$0.12-1.97%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6,280.00% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6,280.00% | -- | -- | -- | -- |
| Cost of Revenue | 5.26% | -12.26% | -12.00% | -9.35% | 9.48% |
| Gross Profit | 69.62% | 51.46% | 28.94% | 10.58% | -8.19% |
| SG&A Expenses | 79.03% | 129.89% | 117.85% | 92.58% | 59.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.64% | 54.14% | 48.37% | 37.63% | 32.08% |
| Operating Income | -12.18% | -33.25% | -39.30% | -36.97% | -31.37% |
| Income Before Tax | -207.62% | 249.91% | 211.84% | 216.38% | 238.32% |
| Income Tax Expenses | -199.34% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -209.86% | 249.68% | 211.69% | 215.93% | 208.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -209.86% | 249.68% | 211.69% | 215.93% | 208.83% |
| EBIT | -12.18% | -33.25% | -39.30% | -36.97% | -31.37% |
| EBITDA | -11.54% | -33.29% | -39.69% | -37.75% | -32.30% |
| EPS Basic | -211.00% | 248.80% | 176.19% | 168.76% | 148.24% |
| Normalized Basic EPS | 11.92% | -80.72% | 14.88% | 40.24% | 23.73% |
| EPS Diluted | -275.28% | 170.42% | 144.35% | 143.52% | 125.28% |
| Normalized Diluted EPS | 5.21% | -60.43% | 22.93% | 46.24% | 30.48% |
| Average Basic Shares Outstanding | 12.09% | 17.18% | 29.05% | 45.45% | 68.96% |
| Average Diluted Shares Outstanding | 4.67% | 17.67% | 28.85% | 44.00% | 65.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |